[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345665-105":59,"doc-detail-345665-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","preclinical-drug-response-profiling-identifies-bmi1-inhibition-as-a-therapeutic-option-for-hepatoblastoma","Preclinical Drug-Response Profiling Identifies BMI1 Inhibition as a Therapeutic Option for Hepatoblastoma","","Hepatoblastoma (HB), the most common pediatric liver cancer, shows substantial variability in therapeutic response despite limited genetic heterogeneity, indicating epigenetic regulation as a key driver of tumor behavior. Integrative analysis of HB patient material and public datasets identified BMI1, a core PRC1 component, as significantly upregulated and linked to aggressive disease and poor survival. Functional screening of epigenetic inhibitors across 15 HB cell lines nominated BMI1 inhibition as the most effective approach, validated by patient-derived xenograft models. PTC596 displayed highest potency, degrading BMI1 and impairing tumor growth through apoptosis induction, with reduced tumor burden and no detectable toxicity in vivo. ",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/preclinical-drug-response-profiling-identifies-bmi1-inhibition-as-a-therapeutic-option-for-hepatoblastoma/345665/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/preclinical-drug-response-profiling-identifies-bmi1-inhibition-as-a-therapeutic-option-for-hepatoblastoma/345665.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is BMI1 considered a promising therapeutic target in hepatoblastoma?","Question",{"text":112,"@type":113},"Integrative profiling showed BMI1 is significantly upregulated in HB, with high expression associated with aggressive disease and poor survival. Functional screening further identified BMI1 inhibition as the most effective strategy across HB models.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does PTC596 affect tumor biology mechanistically?",{"text":117,"@type":113},"PTC596 induces BMI1 degradation and reduces histone H2A ubiquitination. It impairs microtubule dynamics and restores intrinsic apoptosis by shifting the BCL2–BAX balance, leading to caspase-3/7 activation.",{"name":119,"@type":110,"acceptedAnswer":120},"How were in vitro findings connected to in vivo therapeutic effects?",{"text":121,"@type":113},"Predictions from in vitro experiments were strongly concordant with patient-derived xenograft (PDX) responses. In vivo treatment with PTC596 reduced tumor burden and proliferation and promoted proapoptotic signaling without detectable toxicity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345665,1790910657,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Article  \nPreclinical Drug-Response Profiling Identifies BMI1 Inhibition as a Therapeutic Option for Hepatoblastoma  \nSalih Demir 1, Marie Friederike Bentrop 1, Alina Hotes 1, Tanja Schmid 1, Emilie Indersie 2, Sophie Branchereau 3, Christian Vokuhl 4, Beate Häberle 1, Irene Schmid 5, Stefano Cairo 6 and Roland Kappler 1, *  \nAcademic Editor: Elena Tarca  \nReceived: 17 April 2026  \nRevised: 28 May 2026  \nAccepted: 4 June 2026  \nPublished: 10 June 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Pediatric Surgery, Dr. von Hauner Children’s Hospital, University Hospital, LMU Munich, Lindwurmstreet 2a, 80337 Munich, Germany  \n2 XenTech, 91000 Evry, France  \n3 Bicêtre Hospital, AP-HP Paris Saclay University, 94270 Le Kremlin-Bicêtre, France  \n4 Institute of Pathology, University Hospital Bonn, 53127 Bonn, Germany  \n5 Department of Pediatrics, Dr. von Hauner Children’s Hospital, University Hospital, LMU Munich,  \n80337 Munich, Germany  \n6 Champions Oncology, Rockville, MD 20850, USA  \n* Correspondence: roland.kappler@med.uni-muenchen.de  \nAbstract  \nHepatoblastoma (HB), the most common pediatric liver cancer, exhibits marked variability in therapeutic response despite minimal genetic heterogeneity, implicating epigenetic regulation as a key driver of tumor behavior. Among these, polycomb repressor complexes (PRC) remain poorly explored as therapeutic targets. Integrative analysis of samples from patients with HB and public datasets identified BMI1, a core component of PRC1, as significantly upregulated, with high expression strongly associated with aggressive disease and poor survival. Functional screening of epigenetic inhibitors across 15 HB cell lines revealed BMI1 inhibition as the most effective therapeutic strategy, with strong concordance between in vitro predictions and in vivo responses in patient-derived xenograft (PDX) models. The BMI1 inhibitor PTC596 demonstrated the highest potency, consistently suppressing tumor growth across models. Mechanistically, PTC596 induced BMI1 degradation, reduced histone H2A ubiquitination, impaired microtubule dynamics, and restored intrinsic apoptosis by shifting the BCL2–BAX balance, leading to caspase-3/7 activation. Transcriptomic profiling confirmed apoptosis as the most significantly enriched pathway. In vivo, PTC596 markedly reduced tumor burden and proliferation while inducing proapoptotic signaling, without detectable toxicity. Together, these findings establish BMI1 asa critical oncogenic dependency in HB, demonstrate the value of robust preclinical tumor modeling for therapeutic validation, and identify PTC596 as a promising, mechanism-based treatment strategy.  \nKeywords: hepatoblastoma; polycomb repressive complex; BMI1; PTC596; apoptosis  \n1. Introduction  \nClinical trials remain among the most complex and costly stages of drug development, and despite substantial advances in oncology, the failure rate of candidate therapeutics in clinical trials is still unacceptably high [1] . A key contributor to these failures is suboptimal target selection and insufficient understanding of which patient populations are most likely to benefit from a given therapeutic intervention. Robust pre-clinical data that enables patient stratification can markedly increase the likelihood of clinical success by ensuring  \nthat only those patients whose tumors harbor the relevant molecular features are enrolled. Consequently, pre-clinical biological models that faithfully capture both the genomic and phenotypic complexity of cancer, as well as the diversity of therapeutic responses, are essential for de-risking early-stage development [2] . In this context, immortalized cancer cell lines and patient-derived xenografts (PDX) remain essential, and when deployed at scale, are particularly powerful for identifying drug-response","cbCaieUis2rYP9DJ","https://ap.wps.com/l/cbCaieUis2rYP9DJ","pdf",3287676,18,"English","# Abstract\n# Introduction\n## Clinical trial failure drivers\n## Low mutational burden and HB genomics\n## Epigenetic regulation and PRC complexes","[{\"question\":\"Why is BMI1 considered a promising therapeutic target in hepatoblastoma?\",\"answer\":\"Integrative profiling showed BMI1 is significantly upregulated in HB, with high expression associated with aggressive disease and poor survival. Functional screening further identified BMI1 inhibition as the most effective strategy across HB models.\"},{\"question\":\"How does PTC596 affect tumor biology mechanistically?\",\"answer\":\"PTC596 induces BMI1 degradation and reduces histone H2A ubiquitination. It impairs microtubule dynamics and restores intrinsic apoptosis by shifting the BCL2–BAX balance, leading to caspase-3/7 activation.\"},{\"question\":\"How were in vitro findings connected to in vivo therapeutic effects?\",\"answer\":\"Predictions from in vitro experiments were strongly concordant with patient-derived xenograft (PDX) responses. In vivo treatment with PTC596 reduced tumor burden and proliferation and promoted proapoptotic signaling without detectable toxicity.\"}]","Preclinical Drug-Response Profiling Identifies BMI1 Inhibition as a Therapeutic Option for Hepatoblastoma | PDF",1790058507,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/39f47b7679fa7e9f1d18d49e0ee812d2.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ffdd94392ed7e0db5f1cfbca30f5aa0.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b22822045ab341622821b7f0d52761b.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62680ded368f236600ebc05a9d5883ae.webp",980,1385]